Search results for

James Nurton, London

News and photos from MIP's third annual Brand Management Forum, featuring leading in-house counsel and trade mark regulators, held in London at the end of March

Sex, drugs and religion are just some of the subjects that can prompt refusal of trade mark applications on the grounds that they are against public policy or morality. MIP correspondents consider what is banned in different countries, and look at recent cases where the boundaries have been tested (note: some references may cause offence)

Eight out of ten licensors do not perform royalty examinations of their licensees, yet research suggests that in 90% of cases royalties are misreported. Melanie Butler examines what is going wrong and provides some pointers for licensors

Licence agreements in Malaysia are generally governed by the Malaysian Trade Marks Act 1976 and the Contracts Act 1950. Nevertheless, the term "licence" is not expressed in the Trade Marks Act 1976. Instead the licensee is referred to as a "registered user".

Canada's Federal Court gave wide protection to famous marks in its recent Jaguar ruling - but has it gone too far? Mark Evans reviews the decision, and asks whether it will have any effect on two decisions awaited from the Supreme Court

There are an estimated 190 core biotech and 460 biotech-related companies operating in Australia Approximately 35 core biotech companies and 25 biotech-related companies are publicly listed The industry as a whole has raised about A$900 million since the previous industry report in 1999, five times more than estimated in 1998-1999 Revenues generated by core biotech companies over the past 12 months are estimated at almost A$1 billion. Human health, equipment and services, and agriculture are the sectors with the most number of products under development. In 2001 there is an estimated A$300 million of ongoing publicly funded research in biotechnology Victoria has the greatest number of core biotechnology companies (38%) New South Wales has the highest number of biotech-related companies (40%) R&D investment by Australian biotech companies in 1999-2000 was approximately A$150 million. Approximately half the biotech companies operate in the human health sector, including diagnostics and therapeutics Genomics and bio-informatics companies has more than doubled since 1999 Australia's patent system gives it a competitive advantage in attracting foreign companies to invest in the country's biotechnology industry, according to a recently released report on the growth of the sector.

How to stop pirates in Estonia

Nearly one-third of European dot-com companies are failing to protect their trade marks in their home markets, according to a new survey. Even worse, just 60% have registered any trade marks overseas and four out of five have spent nothing on patent protection. The findings come in a survey of 400 senior managers at companies in France, Germany, the Netherlands and the UK. The survey was carried out by Landwell, the correspondent law firm of PricewaterhouseCoopers.

The Singapore-based company and trade mark applicant, Future Enterprises, has for the second time in less than a year faced opposition to its three marks comprising the words "MacTea", "MacNoodles" and "MacChocolate" together with a "device of an eagle" in class 30.